Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes

Toxicology and Applied Pharmacology

Volumn 257, Issue 2, 2011, Pages 198-208

  Yoshino, Yuta ^a   Yuan, Bo ^a,c   Kaise, Toshikazu ^a   Takeichi, Makoto ^b   Tanaka, Sachiko ^a   Hirano, Toshihiko ^a   Kroetz, Deanna L ^c   Toyoda, Hiroo ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b Yoneyama Maternity Hospital   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aquaporin 9; Arsenite; Fetal membranes; Multidrug resistance protein 2; P glycoprotein

Indexed keywords

AQUAPORIN 9; ARSENIC TRIOXIDE; CYCLOSPORIN A; GLYCOPROTEIN P INHIBITOR; LACTATE DEHYDROGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PGP 4008; SORBITOL; UNCLASSIFIED DRUG; VERLUKAST;

AMNION CELL; ARTICLE; CHORION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME RELEASE; FETUS MEMBRANE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

AMNION; AQUAPORINS; ARSENITES; CELL SURVIVAL; CELLS, CULTURED; CHORION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRAEMBRYONIC MEMBRANES; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 81855194085     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.09.006     Document Type: Article

References (38)

1. Andus T., Targan S.R., Deem R., Toyoda H. Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg. Immunol. 1993, 5:11-17.
2. Chattopadhyay S., Bhaumik S., Purkayastha M., Basu S., Nag Chaudhuri A., Das Gupta S. Apoptosis and necrosis in developing brain cells due to arsenic toxicity and protection with antioxidants. Toxicol. Lett. 2002, 136:65-76.
3. Chen G.Q., Shi X.G., Tang W., Xiong S.M., Zhu J., Cai X., Han Z.G., Ni J.H., Shi G.Y., Jia P.M., Liu M.M., He K.L., Niu C., Ma J., Zhang P., Zhang T.D., Paul P., Naoe T., Kitamura K., Miller W., Waxman S., Wang Z.Y., de The H., Chen S.J., Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
4. de Arriba G., de Hornedo J.P., Rubio S.R., Fernández M.C., Martínez S.B., Camarero M.M., Cid T.P. Vitamin E protects against the mitochondrial damage caused by cyclosporin A in LLC-PK1 cells. Toxicol. Appl. Pharmacol. 2009, 239:241-250.
5. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007, 33:542-564.
6. Durak I., Karabacak H.I., Büyükkoçak S., Cimen M.Y., Kaçmaz M., Omeroglu E., Oztürk H.S. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective effects of vitamins E and C. Nephron 1998, 78:207-211.
7. Ferrario D., Collotta A., Carfi M., Bowe G., Vahter M., Hartung T., Gribaldo L. Arsenic induces telomerase expression and maintains telomere length in human cord blood cells. Toxicology 2009, 260:132-141.
8. Fujisawa S., Ohno R., Shigeno K., Sahara N., Nakamura S., Naito K., Kobayashi M., Shinjo K., Takeshita A., Suzuki Y., Hashimoto H., Kinoshita K., Shimoya M., Kaise T., Ohnishi K. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother. Pharmacol. 2007, 59:485-493.
9. Gude N.M., Stevenson J.L., Murthi P., Rogers S., Best J.D., Kalionis B., King R.G. Expression of GLUT12 in the fetal membranes of the human placenta. Placenta 2005, 26:67-72.
10. Kiguchi T., Yoshino Y., Yuan B., Yoshizawa S., Kitahara T., Akahane D., Gotoh M., Kaise T., Toyoda H., Ohyashiki K. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk. Res. 2010, 34:403-405.
11. Lee T.C., Ho I.C. Expression of heme oxygenase in arsenic-resistant human lung adenocarcinoma cells. Cancer Res. 1994, 54:1660-1664.
12. Lee B.D., French K.J., Zhuang Y., Smith C.D. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol. Res. 2003, 14:49-60.
13. Lee T.C., Ho I.C., Lu W.J., Huang J.D. Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J. Biol. Chem. 2006, 281:18401-18407.
14. Leslie E.M., Haimeur A., Waalkes M.P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 2004, 279:32700-32708.
15. Leung J., Pang A., Yuen W.H., Kwong Y.L., Tse E.W. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 2007, 109:740-746.
16. Litzow M.R. Arsenic trioxide. Expert Opin. Pharmacother. 2008, 9:1773-1785.
17. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002, 170:55-62.
18. Liu Z., Carbrey J.M., Agre P., Rosen B.P. Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem. Biophys. Res. Commun. 2004, 316:1178-1185.
19. Liu Z., Sanchez M.A., Jiang X., Boles E., Landfear S.M., Rosen B.P. Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem. Biophys. Res. Commun. 2006, 351:424-430.
20. Mann S.E., Ricke E.A., Yang B.A., Verkman A.S., Taylor R.N. Expression and localization of aquaporin 1 and 3 in human fetal membranes. Am. J. Obstet. Gynecol. 2002, 187:902-907.
21. Matsson P., Pedersen J.M., Norinder U., Bergström C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 2009, 26:1816-1831.
22. McDermott J.R., Jiang X., Beene L.C., Rosen B.P., Liu Z. Pentavalent methylated arsenicals are substrates of human AQP9. Biometals 2010, 23:119-127.
23. Mun K.C., Lee K.T., Choi H.J., Jin K.B., Han S.Y., Park S.B., Kim H.C., Ha E.Y., Kim Y.H. Effects of cyclosporine on the production of the reactive oxygen species in the glial cells. Transplant. Proc. 2008, 40:2742-2743.
24. Ninomiya M., Kajiguchi T., Yamamoto K., Kinoshita T., Emi N., Naoe T. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica 2006, 91:1571-1572.
25. Ohyama K., Oka K., Emura A., Tamura H., Suga T., Bessho T., Hirakawa S., Yamakawa T. Suppression of apoptotic cell death progressed in vitro with incubation of the chorion laeve tissues of human fetal membrane by glucocorticoid. Biol. Pharm. Bull. 1998, 21:1024-1029.
26. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., Baer M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin. Cancer Res. 2005, 11:2320-2326.
27. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48:4827-4833.
28. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., Zhu J., Tang W., Sun G.L., Yang K.Q., Chen Y., Zhou L., Fang Z.W., Wang Y.T., Ma J., Zhang P., Zhang T.D., Chen S.J., Chen Z., Wang Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
29. Shinkai Y., Sumi D., Toyama T., Kaji T., Kumagai Y. Role of aquaporin 9 in cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. Toxicol. Appl. Pharmacol. 2009, 237:232-236.
30. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339:1341-1348.
31. Tsukaguchi H., Shayakul C., Berger U.V., Mackenzie B., Devidas S., Guggino W.B., van Hoek A.N., Hediger M.A. Molecular characterization of a broad selectivity neutral solute channel. J. Biol. Chem. 1998, 273:24737-24743.
32. Wang S., Chen J., Beall M., Zhou W., Ross M.G. Expression of aquaporin 9 in human chorioamniotic membranes and placenta. Am. J. Obstet. Gynecol. 2004, 191:2160-2167.
33. Wang L., Zhou G.B., Liu P., Song J.H., Liang Y., Yan X.J., Xu F., Wang B.S., Mao J.H., Shen Z.X., Chen S.J., Chen Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4826-4831.
34. Yoshino Y., Yuan B., Miyashita S., Iriyama N., Horikoshi A., Shikino O., Toyoda H., Kaise T. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal. Bioanal. Chem. 2009, 393:689-697.
35. Yuan B., Ohyama K., Bessho T., Toyoda H. Contribution of inducible nitric oxide synthase and cyclooxygenase-2 to apoptosis induction in smooth chorion trophoblast cells of human fetal membrane tissues. Biochem. Biophys. Res. Commun. 2006, 341:822-827.
36. Yuan B., Ohyama K., Bessho T., Uchide N., Toyoda H. Imbalance between ROS production and elimination results in apoptosis induction in primary smooth chorion trophoblast cells prepared from human fetal membrane tissues. Life Sci. 2008, 82:623-630.
37. Yuan B., Ohyama K., Takeichi M., Toyoda H. Direct contribution of inducible nitric oxide synthase expression to apoptosis induction in primary smooth chorion trophoblast cells of human fetal membrane tissues. Int. J. Biochem. Cell Biol. 2009, 41:1062-1069.
38. Yuan B., Yoshino Y., Kaise T., Toyoda H. Application of arsenic trioxide therapy for patients with leukemia. Biological Chemistry of As, Sb and Bi 2011, 263-292. John Wiley and Sons, New York. H.Z. Sun (Ed.).